Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Sclerosis, Scleroderma Clear all

Conditions: Systemic Scleroderma, Pulmonary Hypertension
Interventions: Bosentan, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Farmington, Connecticut • Washington D.C., District of Columbia

Conditions: Scleroderma
Interventions: dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Scottsdale, Arizona • Los Angeles, California • Farmington, Connecticut + 10 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Systemic Sclerosis (SSc)
Interventions: Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Sclerosis
Interventions: Nilotinib (Tasigna); Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Scleroderma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Intensity-Modulated Radiation Therapy, Total-Body Irradiation; Procedure · Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Raynaud Phenomenon Secondary to Systemic Sclerosis
Interventions: Placebo IV infusion, Iloprost Injection, for intravenous use; Drug
Lead sponsor: Civi Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Alprostadil, Placebo; Drug · Other
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Interstitial Lung Disease
Interventions: Not listed
Lead sponsor: Pulmonary Care and Research Collaborative Limited; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Scleroderma, Systemic
Interventions: Avenciguat (BI 685509), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more

Conditions: Scleroderma, Digital Ulcers
Interventions: Riociguat, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more

Conditions: Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 513 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Scleroderma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Systemic Sclerosis, Sclerodactyly
Interventions: Hyaluronidase (Hylenex); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Scleroderma, Systemic, Interstitial Lung Disease
Interventions: Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF); Drug
Lead sponsor: Michael Roth; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 17 Years to 90 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Scleroderma
Interventions: MRI, Hyperpolarized Xe129, HRCT; Diagnostic Test · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions: Transcutaneous Electrical Nerve Stimulation; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Sclerosis
Interventions: BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 16 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 17
States / cities: Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions: KYV-101, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Great Neck, New York

Conditions: Scleroderma, Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autoimmune Disease
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 3
States / cities: Iowa City, Iowa • Durham, North Carolina • Research Triangle Park, North Carolina

Search by objective public record fields.

Placebo Controlled Trial of Bosentan in Scleroderma Patients

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Nilotinib in the Treatment of Systemic Sclerosis

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Patient-Reported Outcome Study of Project ECHO for ILD

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

Riociguat in Scleroderma Associated Digital Ulcers

Duke Autoimmunity in Pregnancy Registry

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

Finger Hardness Measure in Scleroderma

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

MRI for Screening and Monitoring Scleroderma ILD

TENS in Scleroderma

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study